HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICCR open to public?

This article was originally published in The Rose Sheet

Executive Summary

At June 19 International Cooperation on Cosmetic Regulation meeting held in Rockville, Md., speakers proposed that future ICCR meetings be opened to the public, with ultimate goal of sharpening cosmetics oversight. Jane Houlihan, VP for research at Environmental Working Group, recommended that "a broad range of stakeholders" be included in ICCR meetings to ensure that "the interests of more than just the regulated industry are represented." Dr. Beth Jordan, medical director of the Association of Reproductive Health Professionals, stated: "We also need to be at the table when regulation and policy that will affect the health and well-being of our patients is being discussed." Both Houlihan and Jordan raised concerns about FDA's oversight of the cosmetics marketplace, specifically the agency's awareness of ingredients being used in personal-care products and their potential health effects. ICCR's first meeting in Brussels in September 2007 covered a range of issues including nanotechnology, good manufacturing practices and alternatives to animal testing (1"The Rose Sheet" Oct. 15, 2007, p. 4). The voluntary effort among the U.S., Canada, EU and Japan was launched with the goal of removing obstacles to international trade. Idea of opening meetings to the public will be discussed at ICCR's next meeting in Washington, DC the week of July 28...

You may also be interested in...

ICCR Addresses Cosmetic Labeling, Nanotechnology At First Meeting

The International Cooperation on Cosmetics Regulation invites the cosmetics industry to generate and submit data showing that U.S. consumers understand the meaning of "trivial names" on product labeling

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts